AxoGen
AXGN
55.75
-0.60
-1.06%
AxoGen
US · AXGN
#2714 by market cap
Listed 1970
55.75
-0.60
-1.06%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.4 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 99.29% -1.35pp
- Institutions
- 314 +6
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund71.31%
Hedge Fund17.69%
Public Company6.34%
Individual/Insider1.91%
Private Company1.71%
Government Pension Fund1.05%
Insurance Company0.73%
VC/PE Fund0.41%
Top holders as of 2026-09-30
BlackRock
7.67% · 4.58M sh
Divisadero Street Capital Management, LP
6.67% · 3.98M sh
First Light Asset Management, LLC
4.60% · 2.75M sh
FMR
4.42% · 2.64M sh
Vanguard Capital Management, LLC
4.07% · 2.43M sh
Morgan Stanley
3.00% · 1.79M sh
Artemis Investment Management LLP
2.98% · 1.78M sh
Geode Capital Management, LLC
2.76% · 1.65M sh
Polar Capital Holdings Plc
2.51% · 1.50M sh
Citadel Advisors LLC
2.32% · 1.36M sh
Wellington Management Group
2.33% · 1.39M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 29 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| Erick DeVinney | Chief Scientific Officer | 0.40% |
| Amy McBride-Wendell | Lead Independent Director | 0.18% |
| Doris Quackenbush | Chief Revenue Officer | 0.15% |
| Jens Kemp | Chief Marketing Officer | 0.12% |
| Lindsey Hartley | Chief Financial Officer | 0.11% |
| Michael Dale | Chief Executive Officer | 0.11% |
| Alan Levine | Independent Director | 0.09% |
| Marc Began | Executive VP, General Counsel, Secretary & Chief Compliance Officer | 0.08% |
| Paul Thomas | Independent Chairperson | 0.05% |
| William Burke | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | Joseph Tyndall | Independent Director | Automatic Disposition | -3,500 | $49.70 |
| 2026-08-10 | Amy McBride-Wendell | Lead Independent Director | Derivative Exercise and Sale | -13,353 | $14.85–48.42 |
| 2026-08-09 | Marc Began | Executive VP, General Counsel, Secretary & Chief Compliance Officer | Derivative Exercise and Sale | -67,500 | $8.16–47.35 |
| 2026-08-06 | Kathy Weiler | Independent Director | Automatic Disposition | -14,150 | $45.30 |
| 2026-06-23 | Paul Thomas | Independent Chairperson | Other Derivative Acquisition | +5,579 | -- |
| 2026-06-23 | Amy McBride-Wendell | Lead Independent Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-23 | John Johnson | Independent Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-23 | Kathy Weiler | Independent Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-23 | Alan Levine | Independent Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-23 | William Burke | Independent Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-23 | Joseph Tyndall | Independent Director | Other Derivative Acquisition | +4,392 | -- |
| 2026-06-18 | Paul Thomas | Independent Chairperson | Derivative Exercise and Retained | +18,867 | -- |
| 2026-06-18 | Amy McBride-Wendell | Lead Independent Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-06-18 | John Johnson | Independent Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-06-18 | Kathy Weiler | Independent Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-06-18 | Alan Levine | Independent Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-06-18 | William Burke | Independent Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-06-18 | Joseph Tyndall | Independent Director | Derivative Exercise and Retained | +14,150 | -- |
| 2026-05-07 | Amy McBride-Wendell | Lead Independent Director | Derivative Exercise and Sale | -1,647 | $14.85–42.60 |
| 2026-05-06 | John Johnson | Independent Director | Derivative Exercise and Sale | -11,050 | $7.04–43.26 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
AxoGen discussion 0 comments